Biogen, Sangamo to Develop Novel Gene Therapies

Biogen, Sangamo to Develop Novel Gene Therapies

288051

Biogen, Sangamo to Develop Novel Gene Therapies

Biogen and Sangamo Therapeutics have begun a collaboration to develop and commercialize gene therapies for Parkinson’s and Alzheimer’s diseases, as well as an undisclosed neuromuscular disease. The five-year collaboration will join Sangamo’s science expertise and proprietary technology with Biogen’s clinical development capabilities. The goal is to submit investigational new drug applications to the U.S. Food and Drug Administration (FDA) and move forward to clinical trials. “We have extensive experience in the discovery and preclinical development of…

You must be logged in to read/download the full post.